Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide

Endocrine Practice

Volumn 18, Issue 1, 2012, Pages

  Iyer, Shridhar N ^a,b   Drake, Almond J ^a,b   West, R Lee ^a   Mendez, Carlos E ^c,d   Tanenberg, Robert J ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLASE; ENALAPRIL; EXENDIN 4; INSULIN; METFORMIN; ROSUVASTATIN; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE PANCREATITIS; ADD ON THERAPY; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CASE REPORT; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HUMAN TISSUE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONITIS; VOMITING; WEIGHT REDUCTION;

EID: 84857573175     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11264.CR     Document Type: Article

References (12)

1. Nitsche CJ, Jamieson N, Lercha MM, Mayerle JV. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24:143-155
2. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retro-spective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349-2354.
3. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
4. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care. 2009;32:834-838.
5. US Food and Drug Administration. Information for healthcare professionals: exenatide: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ucm124713.htm.Accessed September 25, 2011.
6. Lee PH, Stockton MD, Franks AS. Acute pancreati-tis associated with liraglutide. Ann Pharmacother. 2011; 45:e22.
7. US Food and Drug Administration. MedWatch 2009 Safety Alerts for Human Medical Products: Sitagliptin (marketed as Januvia and Janumet) - acute pancreatitis. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm.Accessed September 25, 2011.
8. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract. 2011;17:e48-e50.
9. Nachnani, JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of extendin-4 (exena-tide) on the rat pancreas. Diabetologia. 2010:53:153-159.
10. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endo-crine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009:58:1604-1615.
11. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on gly-cemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
12. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010;33:453-455.